{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-010485","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.243512+00:00","generated_at":"2026-06-14T14:28:38.502907+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Verastem reports 45% ORR for avutometinib+defactinib in RAMP 201 LGSOC trial","bullets":["Combination achieved 45% ORR (13/29 evaluable) and tumor shrinkage in 86% of heavily pretreated LGSOC patients.","KRAS mutant subgroup ORR 60% (9/15); KRAS wild type ORR 29% (4/14); median response time 5.5 months.","Safety profile consistent with prior data; discontinuation rate 12%, mostly due to elevated CPK (4.9%).","FDA Breakthrough Therapy Designation previously granted; company plans filing for accelerated approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-010485","json":"https://secwatch.observer/filing/0001558370-23-010485.json","markdown":"https://secwatch.observer/filing/0001558370-23-010485.md","text":"https://secwatch.observer/filing/0001558370-23-010485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000155837023010485/0001558370-23-010485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000155837023010485/vstm-20230525x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:28:38.502907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}